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Background Mass drug administration (MDA) programmes for neglected 
tropical diseases (NTDs) depend on voluntary community drug distrib-
utors (CDDs) to deliver drugs, and these volunteer schemes need regular 
training and supervision. NTD policy now includes integration of multiple 
disease programmes, but we are unsure if there is clarity in what is current-
ly expected of CDDs and how they are managed. We therefore analysed 
World Health Organization (WHO) policy, strategy and implementation 
guidance, and select national NTD programme implementation plans.
Methods Included are a) WHO global and WHO-Regional Office for Af-
rica guidelines, strategies, operational manuals and meeting reports pub-
lished between January 2007 to February 2018 that included policy and 
plans for CDDs; and b) national NTD programme master plans for Camer-
oon, Ghana, Liberia and Nigeria. For both review components, we exam-
ined the CDD responsibilities through a framework developed iteratively 
against the documents and prepared a narrative synthesis.
Results Twenty WHO policy documents met the inclusion criteria. In the 
twelve global and eight regional documents, the CDD role was not ex-
plicitly or comprehensively defined. Three documents mentioned CDDs 
will distribute drugs; some mentioned health promotion, data handling 
and engagement in clinical care. Four WHO documents noted a need for 
CDD training or management, eight detailed some aspect of this, and one 
regional document provided a comprehensive overview. In the national 
plans, additional responsibilities included case management in two coun-
tries and transmission control in two countries. Every plan included train-
ing and supervision, but this was not always explicit, and details of the 
purpose and frequency varied. In all national plans, CDD motivation was 
identified as a challenge but not comprehensively addressed, although one 
document mentioned provision of bicycles.
Conclusions WHO and national policies and plans assume CDDs will im-
plement NTD programmes. However, there is almost no clear delineation 
of responsibilities, nor is there up-to-date practical guidance to guide man-
agers. This ambiguity, in relation to the lack of explicit policies or program-
matic guidance, probably impairs the effectiveness of NTD programmes.
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This project
We were part of development teams to supporting sustainable scaling up 
of mass drug administration (MDA) campaigns in Cameroon, Liberia, Gha-
na and Nigeria (http://countdown.lstmed.ac.uk/), and were asked to exam-
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ine the evidence around volunteer community drug distributors (CDDs) in neglected tropical disease 
(NTD) programmes.
In our initial appraisal, we identified clear benchmarks in relation to a World Health Organization (WHO) 
affiliated training document for CDDs published in 1998 [1] but found more recent policies relating to 
CDDs were not as well-defined. As this cadre appears to be central to global programmes distributing 
freely donated drugs [2], we wondered how clear are policies and procedures set by WHO or national 
programmes to assure their distribution by CDDs? What are the explicit responsibilities of CDDs in con-
temporary MDA programmes for NTDs in Africa?
We address these questions in this analysis, but we first provide a brief overview of the history of NTD 
policy from 1995 to present day. We then systematically sought and analysed the CDDs role as pre-
sented in a) global and regional policy documents for Africa; and b) in select national NTD programme 
master plans.
Historical overview
The WHO currently recognises 20 communicable diseases prevalent in tropical and subtropical conditions 
worldwide [3], collectively called neglected tropical diseases or NTDs. NTDs are associated with pover-
ty, and primarily impact populations in low-income and middle-income countries with limited access to 
under-resourced health services [4]. NTDs are a diverse group of infections and conditions that adverse-
ly impact mental health [5], and cause considerable morbidity [6], social stigma [7] and death [8]. The 
African Region alone suffers around 40% of the global burden of NTDs [9].
Five NTDs – onchocerciasis, lymphatic filariasis, soil-transmitted helminthiasis (STHs), schistosomia-
sis and trachoma – can be managed through preventive chemotherapy (PC) and are termed PC-NTDs. 
When given annually or semi-annually to the entire population at risk (MDA) or specific at-risk groups 
(targeted treatment), PC can treat individuals for the infection, prevent new morbidity developing over 
time and reduce or interrupt disease transmission [10]. Of the 47 countries in the WHO African Region, 
44 are endemic for one or more NTDs that are amenable to PC, and 17 countries are co-endemic for five 
of these diseases [2].
Control programmes require repeated rounds of drug delivery over several years to endemic areas, with high 
therapeutic and geographic coverage, to meet the public health targets for the PC-NTDs. Community-based 
delivery of PC is dependent on a cadre of health volunteers, termed community drug distributors or CDDs, 
to distribute treatment within their communities, particularly in hard to reach and remote areas [2].
Origins
The community-directed treatment (ComDT) approach engaging volunteer CDDs for drug distribution 
was developed by the WHO and Special Programme for Research and Training in Tropical Diseases (TDR), 
and subsequently adopted by the African Programme for Onchocerciasis Control (APOC) in the late 1990s 
after a multi-country study showed that use of CDDs was a feasible and effective approach to deliver iver-
mectin for onchocerciasis [11]. This strategy became known as community-directed treatment with iver-
mectin (CDTI). CDDs were related but seen as separate to community health workers (CHWs), who often 
had a broader role in communities with health promotion and advice and could be paid for their services.
The “Practical Guide for Trainers of Community-Directed Distributors” was published by APOC in 1998, 
and CDDs were described as “villagers who have been selected by their communities to carry out the 
task of distributing ivermectin to other members of their community” [1]. This document was extensive 
and included detailed guidance on how CDDs should be selected, how to conduct their training and 
tasks for the trainee CDD post-training. Responsibilities of CDDs included conducting a village census 
to determine the quantity of drugs required, keeping a drug inventory, keeping records and liaising with 
health workers, providing the correct drug dosage, excluding people ineligible for treatment (pregnant 
and breastfeeding women, sick people) and referring people experiencing adverse reactions to a health 
facility [1]. The community was responsible for incentivising CDDs, and sustainability of the programme 
stemmed from greater ownership and empowering communities to have control over their own health.
Integration
Following the initial success of the CDTI strategy, which included 20 million people being treated annu-
ally and 67 000 CDDs trained by 2001 [12], the CDTI network was soon used to deliver additional com-
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munity health services [12,13] and explored by other NTD programmes, including lymphatic filariasis 
[14] and schistosomiasis and STHs [15].
In 2003 and 2005, the WHO held international workshops that coined the collective term “neglected 
tropical diseases” and started the transition from vertical disease-centred approaches to an integrated 
community-centric approach [16,17]. The narrative changed to the promotion of integrated NTD pro-
grammes, where many of the PC-NTDs have overlapping geographical distributions and treatment reg-
imens [10,18-21]. In 2006, the WHO launched a new drug strategy for integrated PC for helminthiasis 
[10], and the United States Agency for International Development (USAID) established the NTD Control 
Program (NTDCP) to test integration on a large scale and facilitate expansion of integrated treatment in 
select national programmes [22,23].
The first “Global Plan to combat Neglected Tropical Diseases (2008-2015)”, published by the WHO in 
2007, then endorsed integrating NTD control programmes worldwide with co-implementation of PC as 
a ‘drug package’ [24]. The NTD Roadmap was later published to guide implementation of the policies 
and strategies outlined in the global NTD plan, and quickly followed by support from the London Dec-
laration on NTDs [25].
In the WHO African Region, integrated PC is currently a priority intervention in the “Regional Strategy 
on NTDs in the WHO African Region (2014-2020)” and includes the co-implementation of communi-
ty-directed interventions (CDI) [26]. Country-specific strategies for integrated NTD control and elim-
ination are stipulated in the multi-year master plan for national NTD programmes, in accordance with 
WHO guidelines [27].
Objective
To delineate the role of CDDs in contemporary MDA programmes for NTDs in the African Region, as 
defined in global and regional policy documents; and as outlined in a selection of national NTD pro-
gramme master plans.
METHODS
Inclusion criteria
For the policy documents, we included documents from WHO global programmes and documents from 
the WHO Regional Office for Africa (WHO-AFRO). We sought WHO guidelines, strategies, operational 
manuals and meeting reports published between January 2007 to February 2018 that included policy 
and plans for CDDs in PC-NTD programmes. Reports of meetings were included if there were recom-
mendations or action points relating to CDDs. We took 2007 as the starting point given the establishment 
of worldwide NTD policy by the WHO in this year, which included the first global partner’s meeting on 
NTDs [28] and publication of the global NTD plan [24]. This set the international agenda for NTD pre-
vention, control, elimination or eradication, and we would expect any resultant changes in the expecta-
tions of CDDs and their management to be outlined clearly in the policies and plans that followed.
Exclusion criteria consisted of documents described as “working drafts”, reports, documents that only 
referred to CDDs and related terms in the introductory sections or in a “situation analysis”, “update” or 
“progress report”, and documents that referred only to CDI or CDTI without clear reference to CDD in-
volvement.
For the second objective, we sought the NTD programme master plans from Cameroon, Ghana, Li-
beria, and Nigeria. These countries were selected as they all receive financial and technical support 
from the COUNTDOWN consortium (a Department for International Development (DFID)-funded 
project). These countries use the standard NTD programme template and were selected to be part of 
the COUNTDOWN consortium as they are all in different phases of NTD control (https://countdown.
lstmed.ac.uk/).
Definition of a community drug distributor
The CDD cadre has various labels and expectations, and so our definition is: “a volunteer who is selected 
by the community to distribute drugs for diseases targeted by NTD programmes”. This includes volun-
teers that participate in MDA to all members of a community and volunteers involved in targeted treat-
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ment of specific at-risk groups in the community [10]. Within the context of this review, we use a slight-
ly modified definition of the CHW described by Lewin et al [29] to include any health volunteer who:
• performs functions related to drug distribution to prevent selected NTDs;
• is trained in some way in the context of the intervention; but
• has no formal professional or paraprofessional certificate or tertiary education degree.
This definition of the CDD cadre excludes teachers, frontline health workers and other individuals who 
may be involved in drug distribution in conjunction with their salaried employment.
Policy documents
Search
We attempted to identify all relevant WHO policy documents published between January 2007 to Febru-
ary 2018 by searching https://www.who.int with “Global” as the regional site (English only), the WHO-AF-
RO Library and the WHO IRIS AFRO collections (no language restrictions) using the search terms and 
subjects listed in Table S1 in Online Supplementary Document. We also searched the APOC website 
and the Expanded Special Project for Elimination of Neglected Tropical Diseases (ESPEN) portal resources 
for publications. We noted any documents that are currently in preparation or documents we are aware 
of but unable to obtain a copy. We engaged with experts from the research, advocacy and policy sectors 
in the field of NTDs to ensure inclusivity of all relevant policy documents.
Selection
Records identified from the search strategy were combined and titles screened to remove duplicate and 
irrelevant records. Records that were clearly not policy documents, such as WHO Weekly Epidemiolog-
ical Reports, brochures and newsletters, were excluded.
Data identification
Full-text copies of all potentially relevant policy documents were obtained and assessed by one author 
based on the inclusion criteria using NVivo 11 Software (QSR International, Melbourne, Australia). Text 
search was used to identify sought-after text, such as “distributor”, in each document, applying the “with 
stemmed words” setting to identify similar text (eg, distributors). The list of text terms is provided in Ta-
ble S1 in the Online Supplementary Document. When it was unclear, a second author was consult-
ed. Ineligible documents and the reasons for their exclusion were listed in a “characteristics of excluded 
documents” table.
Data extraction
Pre-tested data extraction forms were used to manage the data. We extracted information on the type 
of document, the publication date, the scope of the document (global or regional policy), the disease(s) 
covered and statements relevant to the drug distributor identified through the NVivo text search. For 
each document, the statements were organised into groups, including: 1. assertions about their role; 2. 
recommendations for their role; 3. reference to their training and management; and 4. other comments 
about CDDs.
Data analysis
We prepared a narrative synthesis of the role of CDDs as is documented in global and regional documents. 
We examined the documents and the data and then used this to inform the categories. Documents were 
assessed using four broad categories that were subdivided to reflect the description of the CDDs role, the 
strength of the policy, and the level of detail provided:
1.  Specifying aspects of the CDDs role. The main options were drug distribution, data collection, health 
promotion, and a role in clinical care.
2.  Recommendations for the CDDs role. Options included: none, an option with caveats, an option, 
and a formal recommendation.
3.  Strategies for training and managing CDDs. Options included: no strategies, notes need, comment 
on aspects, and clearly and comprehensively outlined.
4. Other comments about CDDs.
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We considered “specifying aspects of the CDDs role” as a directive statement about an activity CDDs are 
or will be involved in, while “other comments about CDDs” were more general statements that included 
other relevant information about CDDs but were not instructional.
National programme master plans
The national NTD programme master plans follow the structure recommended in the WHO “Guide for 
preparing a master plan for national NTD programmes in the African region” (Figure 1) [27], and include 
the national objectives, goals and a 3-5 year strategy to guide programme planning and implementation. 
We obtained the most recent national NTD master plan from Cameroon, Liberia, Nigeria and Ghana 
through the COUNTDOWN consortium and the ESPEN portal resources.
Figure 1. Major components of neglected tropical disease programme master plans for the African  
Region outlined by the World Health Organization [27].
Data extraction
Data extraction recorded the date of publication the date of publication and period covered by the plan, 
the disease(s) covered and information relevant to the drug distributor, including the diseases requiring 
drug delivery by CDDs, any other activities CDDs are implicated in, details of training and supervision, 
and whether incentives are included. Prior to using text search to extract relevant data, we scoped the 
master plan glossaries and introductory “situation analysis” sections to identify any other country-specif-
ic terms for CDDs. We then conducted the same text search as was used for the global and regional doc-
uments, with the addition of any country-specific terms for CDDs and the terms supervis* and train*.
Data analysis
A narrative synthesis was prepared to document the intended role of CDDs as it is outlined in the NTD 
programme plans of Cameroon, Ghana, Liberia and Nigeria. Statements in the plans regarding CDDs were 
analysed by compiling information relating to:
1.  Anticipated role of CDDs, plus any additional activities of volunteers mentioned in the “situation 
analysis”.
2. Strategies for training and management.
3. Motivation and incentives (motivation is acknowledged, and incentives included).
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RESULTS
Policy documents
Twenty documents in 24 records met the inclusion criteria (Figure 2). One document, the regional strat-
egy on NTDs in the WHO African Region [26], had three related records [26,30-32] but there was no 
difference in relation to content on CDDs, so we report this as one document [26]. Another document 
[33] had one related record [34], which was a shorter overview of a curriculum, and we report on the 
more comprehensive document [33]. We excluded 199 full-text documents that did not meet the inclu-
sion criteria, including five documents that we were unable to source an electric copy of [35-39], and two 
documents that were “working drafts” and subject to further revision [40,41]. We included one “work-
ing draft” as it was recommended that the tool be made 
available to national programmes for immediate use [42].
Global
Of the 20 documents relevant to CDDs, 12 were global 
in scope. Six documents were about lymphatic filariasis 
(two described as “strategy”, and the other four variously 
described as “aide-memoire”, meeting report, handbook 
and manual; Table 1, column 1). The remaining six doc-
uments were about the PC-NTDS (described as guide, 
manual, practical advice, tool and training course (2)). 
Supportive evidence is provided in Table S2 in Online 
Supplementary Document.
Specifying aspects of the CDDs role: Of the 12 docu-
ments, seven made no reference to the responsibilities of 
CDDs in MDA (Table 1, column 3). Two training docu-
ments specified that CDDs have a role in drug delivery, 
stating that “CDDs play a critical role in distribution” and 
are responsible for leading “absentee and post-MDA fol-
low-up”. CDDs are also involved in distributing infor-Figure 2. PRISMA flow diagram.
Table 1. Global documents.
Column 1 2 3 4 5 6
Year [ref] Type of document* Disease(s) 
covered
Specifying aspects of the 
CDDs role?
Recommendations for 
the CDDs role?
Strategies for training 
and managing CDDs?
Other comments 
about CDDs†
2010 [43] “Strategic plan” LF No None No Included
2012 [44] “Provisional strategy” LF‡ No An option with caveats Notes need None
2013 [45] “Aide-memoire” LF No None Notes need None
2016 [46] “Meeting report” LF No None Comment on aspects None
2016b [47] “Guide” PC-NTDs No None Comment on aspects Included
2013b [48] “Handbook” LF No An option Notes need None
2010 [49] “Manual” PC-NTDs Data collection None Comment on aspects Included
2011 [50] “Manual” LF Data collection None Comment on aspects Included
2011 [51] “Practical advice” PC-NTDs Clinical care None No Included
2016c [42] “Tool” PC-NTDs No None Comment on aspects Included
2015 [52] “Training course” PC-NTDs§
Drug distribution;  
data collection; health  
promotion; clinical care
None Comment on aspects Included
2015b [53] “Training course” PC-NTDs
Drug distribution;  
data collection; health  
promotion; clinical care
None Comment on aspects Included
CDD – community drug distributor, LF – lymphatic filariasis, PC-NTDs – preventive chemotherapy neglected tropical diseases, ref – reference
*Type of document is the words in the title that best classify the document.
†Comments about CDDs provided in the document’s “background/introduction”, or in a “progress report”, an “update” or a “current situation”, were 
not included as other comments about CDDs in policy.
‡Loiasis and malaria are also included in document.
§Also mentions foodborne trematodiases.
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mation, education and communication (IEC) materials and “other service delivery (MMDP)” (morbidity 
management and disability prevention). Some documents indicated that CDDs should carry out other 
tasks, including:
•  collecting, recording and reporting information (four documents), such as completing PC tally 
sheet forms or registers, leading the community census and “monitoring inventory of logistics”.
•  health promotion (two documents), including leading community meetings, sensitisation and mo-
bilisation, conducting IEC activities before and while distributing interventions, and lymphoede-
ma/hydrocele case finding by going door-to-door to “disseminate the message”.
•  clinical management role (three documents), including assisting with adverse events (AEs) and 
referring people to a health facility, and record and report AEs. Actions for CDDs to manage AEs 
were provided, with a list of common AEs or symptoms, their frequency and treatment. There was 
an emphasis on drug safety (CDDs understanding treatment exclusion criteria, awareness of issues 
relating to treating children) and CDDs performing adequately (“CDDs must give the right infor-
mation”, “CDD… and child should be relax, calm, friendly”).
None made clear exactly what CDDs should do, or how they should do it.
Recommendations for the CDDs role: There were no recommendations for CDDs. Two documents 
for lymphatic filariasis mentioned CDDs may be of use to malaria programmes by encouraging net use.
Strategies for training and management: No document provided a comprehensive training and man-
agement strategy for CDDs. Two documents did not mention the topic, and three commented on the need 
for training and supervision but gave no further information. In the remaining seven, two training course 
documents provided some information of practical help for training. For example, “CDDs are commu-
nity members who will be selected by the communities to undertake the task of drug distribution”, the 
number of CDDs per hamlet to train (two), the gender ratio of CDD teams (“as much as possible choose 
a team of two people, a man and a woman”) and length of training period (between two days). A list of 
what to include in CDD training was provided: “Diseases: Very brief description of diseases targeted, MDA 
strategy; Drugs: What drugs to use, Dosage, including use of dose poles; How to administer, Exclusion 
criteria, AEs/SAEs identification, management and referral; Register/Tally Sheets”.
For CDD management, a training course included “Regular supervision and monitoring in the commu-
nity”, and the responsibilities of the different personnel overseeing CDDs was detailed. Some documents 
highlighted a need to inform community volunteers of the results of their work and discuss problems, 
including “drug administration, remuneration, compliance, IEC, form filling, use of remaining drugs…”. 
Four documents included practical guidance for monitoring, with corrective actions to take with CDDs 
when interpreting and following up reported and surveyed coverage results, and in the event of Trans-
mission Assessment Survey1 (TAS1) failure.
Other comments about CDDs: Scattered through the documents were statements that indirectly referred 
to the CDDs role and how they should be managed. This included benefits and challenges of integration 
for CDDs, such as “improved supervision of community drug distributors (CDDs)… with fewer resources” 
and “increasing demands are being placed on volunteers as other programmes recognize their potential”. 
One document noted that “…for volunteers to deliver chemotherapy for a variety of NTDs and provide 
other health services, it will be necessary for health systems to create clear job descriptions, standardize 
incentives across programmes, and coordinate efforts to build capacity”.
Other statements mostly centred around CDD performance, such as data quality concerns, operational 
errors and CDD attitude, and preparation for MDA, preparation for MDA, which consists of selection of 
CDDsCDDs (two people, a man and a woman, selected by the community or by district level personnel), 
mode of drug distribution (eg, house-to-house, from a central point, areas where people congregate or 
determined by the District NTD coordinator) and the MDA commodities required.
Regional
We identified eight regional documents. Five documents were about onchocerciasis (described as meet-
ing reports (4) and handbook; Table 2, column 1), and one document was about onchocerciasis and 
lymphatic filariasis (described as “strategic plan of action”). The remaining two documents were about 
NTDs (described as “strategy” and meeting report). Supportive evidence is provided in Table S3 in the 
Online Supplementary Document.
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Specifying aspects of the CDDs role: Of the eight documents, seven made no reference to the role of 
CDDs (Table 2, column 3). One document, a trainers’ handbook for a curriculum and training module 
on the CDI strategy for medical and nursing students, stated “Implementation of the intervention by com-
munity implementers” consists of “delivery of the interventions”. Specific tasks that CDDs are responsi-
ble for performing included:
• “attend training and other educational programmes in respect of the intervention programme;
• provide information, education and communication to the community;
• conduct census and estimate the population that will need the service;
• collect or ensure that intervention commodities are available in the community;
• keep record of how the intervention was delivered;
• submit a record of intervention to the supply collection point;
• provide feedback to the community.”
The document outlines the community’s role in planning and decision-making for CDI, although given 
that the decisions about the drugs and the diseases targeted are already made, it is not clear what these 
decisions are really. There is almost no guidance for appropriate CDD workload and the number of inter-
ventions or other services volunteers can be responsible for.
Recommendations for the CDDs role: One of the eight documents made a recommendation about 
CDDs. The Joint Action Forum (JAF) for onchocerciasis control “strongly endorsed” a change in the ratio 
of CDDs to people treated, from one CDD for up to 250 people to one CDD for up to 100 people. One 
document provided an option for CDDs to carry out sensitisation on skin NTDs during MDA and one 
document listed several potential interventions for volunteer distribution, including maintain and distrib-
ute bed net supplies, and case management of malaria, pneumonia and diarrhoea.
Strategies for training and management: Five documents did not mention the topic, and one endorsed 
the need for training more women CDDs but no further information. One document provided a few vague 
options for managing CDDs dwindling motivation to work on a voluntary basis over an extended period.
One document outlined a comprehensive curriculum on the CDI strategy for students in medical and 
nursing schools. The guidance in this trainers’ handbook included units on “setting up the CDI strat-
egy”, “supervision” and “monitoring and evaluation”. Setting up the CDI strategy in a community was 
described in detail and included use of the APOC video for training CDDs. Instructions for conduct-
ing CDD training were not included but use of the original APOC training manual for CDDs was rec-
ommended, with audio visuals by NTD support initiatives where the training requires multiple inter-
Table 2. Regional documents.
Column 1 2 3 4 5 6
Year [ref] Type of document* Disease(s) covered Specifying aspects 
of the CDDs role?
Recommendations 
for the CDDs role?
Strategies for training 
and managing CDDs?
Other comments 
about CDDs†
2014 [26] “Strategy” NTDs No None No Included
2013 [54]
“Strategic plan of 
action”
LF and  
onchocerciasis
No None Comment on aspects Included
2007 [55] “Meeting report” Onchocerciasis No
Formal  
recommendation
No None
2008 [56] “Meeting report” Onchocerciasis No None No Included
2009 [57] “Meeting report” Onchocerciasis No None No Included
2012 [58] “Meeting report” Onchocerciasis No None Notes need Included
2017 [59] “Meeting report” NTDs‡ No An option No None
2012b 
[33]
“Handbook” Onchocerciasis§
Drug distribution; 
data collection; 
health promotion
An option
Clearly and compre-
hensively outlined
Included
CDD – community drug distributor, LF – lymphatic filariasis, NTD – neglected tropical diseases, ref – reference
*Type of document is the words in the title that best classify the document.
†Comments about CDDs provided in the document “background/introduction”, or in a “progress report”, an “update” or a “current situation”, were 
not included as other comments about CDDs in policy.
‡Addresses preventive chemotherapy NTDs and case management NTDs.
§Also mentions other diseases that may use community-directed interventions, such as lymphatic filariasis, schistosomiasis, trachoma and malaria 
(bed nets).
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ventions, such as distributing bed nets and drugs for other NTDs. Two to three days should also be 
allocated for training CDDs.
For management, the CDI trainers’ handbook included the frequency of supervision for CDDs (twice 
monthly), the supervisor role and tools, and examples of forms and checklists for supervision and mon-
itoring (such as “Integrated supervision checklist for PHC programmes” and “Supervision checklist for 
CDTI”). Examples of problems that can be encountered during supervision and possible solutions/actions 
were provided, as well as examples of CDD supervision tasks.
Other comments about CDDs: Statements concerning CDDs were included in six of the eight docu-
ments. The trainers’ handbook for CDI contained general statements throughout, including the commu-
nity’s role in incentivising CDDs, CDD selection (community informed of selection criteria and then com-
munity selects implementers) and modes of drug distribution (door-to-door, community visits volunteer’s 
home, or at a central place). Two other documents included statements regarding incentives for CDDs, 
and one document acknowledged CDDs use in case finding for “eye care”. The AFRO-regional strategy 
stated that “Cross-cutting interventions or activities… should be harmonized and streamlined…”. Listed 
among the interventions and activities was “involvement of community volunteers or medicine distrib-
utors”. For supporting morbidity management, one document specified that “involvement and collabo-
ration of patients and their families, community volunteers and community health workers is essential”.
National programme master plans
We obtained the current NTD master plan for Cameroon (2016-2020), Ghana (2016-2020), Liberia 
(2016-2020) and Nigeria (2015-2020). The Cameroon master plan is currently a draft and available in 
French only. This plan was translated to English, and we acknowledge that the plan may be less formu-
lated in its’ current format as a draft document. The plans range from 61 to 148 pages in length and con-
sist of the main WHO recommended sections [27], including: situational analysis, NTD strategic agen-
da and operational framework, as well as budget justification and estimates (Figure 1). Our analysis is 
summarised in Table 3.
Anticipated role of CDDs: Each plan includes a table summarising the disease-specific goals and objec-
tives, which generally indicates the main strategies/interventions, delivery channels and target population 
for each targeted disease. Community-based MDA is the strategy for onchocerciasis and lymphatic filariasis 
in all four plans, and for trachoma in Nigeria and Cameroon where the disease is endemic. All countries 
are endemic for schistosomiasis and STHs, and the strategy for schistosomiasis in the four plans and for 
STHs in three plans (excluding Ghana) consists of community-based targeted treatment to specific at-risk 
groups. Use of CDTI/CDI is indicated as the “delivery channel” in some of the strategies, but only the Li-
beria plan specifically mentions “community health volunteers” for STHs. Three of the plans (excluding 
Cameroon) provide a table detailing the packages of MDA, with “training community volunteers” as an 
overall requirement, implying their involvement in drug delivery. MDA is also included for yaws in two 
plans (Ghana and Liberia), but this requires health workers in Ghana and it is unclear whether commu-
nity-wide treatment requires “staff” or volunteers in Liberia.
For case management and chronic care, two plans (Ghana and Liberia) include NTD volunteers. In Gha-
na, volunteers will conduct “Case search and management”, and in Liberia, volunteers are implicated in 
routine active case detection and referral for ‘case management’ NTDs. For transmission control, two plans 
(Liberia and Nigeria) include volunteers. In Liberia, a community health volunteer (CHV) in each commu-
nity will distribute insecticide treated nets (ITNs), and in Nigeria, community volunteers will be trained 
to use “LLINs, IRS and personal hygiene” (long lasting insecticidal nets, indoor residual spraying). The 
Liberia plan also includes health promotion, such as conducting meetings and providing kits and train-
ing to “affected individuals” to enable “home based self-care for CM-NTDs” (case management NTDs).
Two plans (Cameroon and Liberia) acknowledge other activities NTD volunteers have been involved 
with, including: delivering bed nets, vitamin A and immunisations, “family planning interventions ORS 
and zinc”, identifying scrotal swelling and lymphedema cases, detection and referral of suspicious lep-
rosy cases, social mobilisation, contact tracing, health education and “member of burial teams…during 
the EVD outbreak”. The Nigeria plan also states that CDTI provided entry points for other communi-
ty-based interventions.
Strategies for training and management: All the country master plans include aspects of training and 
supervision, but details on the frequency and individuals responsible for training and managing CDDs 
are not always described.
Macfarlane et al.
December 2019  •  Vol. 9 No. 2 •  020414 10 www.jogh.org •  doi: 10.7189/jogh.09.020414
V
IE
W
PO
IN
TS
PA
PE
RS
For training, the Cameroon plan specifies annual training of “community agents” and “community actors 
in social mobilization”, and community relay training in data management. For Ghana, “training of… 
community based volunteers will be done… jointly for all the diseases”. CDDs will be trained to conduct 
MDA by “personnel” twice a year. The Liberia plan includes training of community volunteers “on inte-
grated NTD activities” quarterly over 2017-2020, and training of a CHV in the third quarter annually to 
distribute bed nets. For case management, “… community volunteers (especially CDDs) shall be trained 
in the suspicion cases during CDI activities, and referral of suspected cases to the health facilities...”, with 
integrated in-service cascade training of CHVs. For Nigeria, a priority is “comprehensive capacity build-
ing of NTD staff and volunteers at all levels on integrated NTDs”. The plan includes annual training of 
community NTD implementers to use “data collection reporting tools”, and on the use of “LLINs, IRS 
and personal hygiene” (requiring training of health workers to conduct training).
For supervision, the Cameroon plan includes “supervision of community-based actions” annually. In the 
Ghana plan, “personnel” and district staff are needed to monitor CDD training over 2013–2017. For MDA, 
“personnel” are required to “conduct monitoring and supervision at all levels” in periods “Q2, Q3, and 
Q4”. Sub-district monthly reviews over 2013-2017 will also require “transport for CDDs”. Supervision 
Table 3. The role of community drug distributors in national neglected tropical diseases programme master plans for Cameroon, 
Ghana, Liberia and Nigeria*
national plan ntD programme master plan
Country Cameroon Ghana Liberia Nigeria
Period 2016-2020 2016-2020 2016-2020 2015-2020
Anticipat-
ed role of 
CDDs
NTD programme Disease
Drug distribution Onchocerciasis MDA MDA MDA MDA
LF MDA MDA MDA MDA
Schistosomiasis Targeted Targeted Targeted Targeted
STHs Targeted Not required Targeted Targeted
Trachoma MDA Not required Not required MDA
Other NTDs Not required Not required Unclear* Not required
Case management and chronic care Not included Yes Yes Not included
Transmission control (eg, bed net delivery) Not included Not included Yes Yes
Other activities documented (eg, vitamin A distribution) Yes Not included Yes Yes
Training Required by plan? Required Required Required Required
Who will train? Not specified “Personnel” Not specified† Not specified‡
Frequency of training Annually Q2 and Q4 Q1, Q2, Q3, Q4, p.a. Annually§
Supervision Required by plan? Required‖ Required Required Required
Who will supervise? Not specified “Personnel” Not specified† Not specified
Frequency of supervision Annually‖ Q2, Q3, Q4. 
Monthly sub-dis-
trict review meet-
ing (CDDs)¶
Not specified. 
Monthly meeting 
with health facility 
OIC (CHVs)
Not specified
Incentives Included in plan? Unclear** Not included Bicycles Usable IEC  
materials
CDD – community drug distributor, CHV – community health volunteer, IEC – information, education and communication, LF – lymphatic filariasis, 
MDA – mass drug administration, NTD – neglected tropical diseases, OIC – Officer in Charge, p.a. – per annum, STH – soil-transmitted helminths.
*We refer to “MDA” when mass drug administration is indicated, and “targeted” when treatment appears to be indicated for specific groups. We an-
ticipated the distributors involvement when the drug delivery strategy included terms such as “community-based”, “community directed intervention 
(CDI)”, and “community directed treatment with ivermectin (CDTI)”. The Liberia plan indicates community MDA for yaws but it is not clear whether 
this requires community volunteers or “staff”.
†The Liberia plan did not identify the trainer and supervisor of CDDs, although the “situation analysis” indicates this requires “health facility staff”. For 
case management NTDs, cascade training will be used.
‡Training of CDDs for MDA is not described in the Nigeria plan. Training community implementers on the use of “LLINs, IRS and personal hygiene” 
requires training of health workers.
§The Nigeria plan includes annual training of “community NTD implementers on the use of data collection reporting tools”, but overall training for 
CDDs is not indicated.
‖The Cameroon plan specifies “supervision of community-based actions”.
¶The Ghana plan states “conduct monitoring and supervision at all levels” for MDA. Sub-district monthly review meetings require “transport for CDDs”.
**“Motivate community actors” annually is in Cameroon’s plan but no further details.
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is listed as a requirement in the Liberia and Nigeria plans, and Liberia also plans to “integrate NTDs into 
monthly meeting of CHVs/CHA with health facility OIC to report on conditions within the community”. 
However, no further details on CDD management are provided.
Motivation and incentives: As part of the situation analysis, all plans include a strengths, weaknesses, 
opportunities and threats (SWOT) analysis for the NTD programme. The plans all include the presence of 
“mobilizable”, “committed” or “trained” CDDs in communities as a strength or opportunity, but also note 
challenges. The Cameroon and Ghana plans indicate lack of motivation as an issue, as well as the demand 
for incentives and ageing of the distributors. The Ghana and Liberia plans recognise that volunteers can 
be demotivated by other non-governmental organisation (NGO) activities and competing health activi-
ties and incentives between programmes. The Liberia plan states that “… lack of funding and incentives 
are an ongoing challenge for CDDs”, but CDDs could be involved in income generating activities through 
collaboration with development NGOs and Agriculture Ministry. For the Nigeria NTD programme, high 
attrition, low commitment and inadequate numbers of trained community implementers are challenges.
For proposed activities, the Cameroon plan states “encourage communities to document motivation mech-
anisms of community workers”, with development and dissemination of “motivation reporting tools for 
community workers”. “Motivate community actors” annually is also part of the plan, but no details are 
provided. Incentives for CDDs in Liberia include “procure 3000 bicycles for CDDs” in the second quarter 
of 2017. In Nigeria, a priority is the “provision of incentives in form of usable IEC materials”. The Ghana 
plan does not include incentives for CDDs.
DISCUSSION
The role of CDDs has changed over the years since APOC first started using the CDTI implementation 
model. With the intensified drive to meet current global health targets for NTDs controlled by drugs, de-
livery of PC by community volunteers appears critical for programme success but could potentially be a 
weak link [60-62]. This review consolidated the evidence from more recent WHO global and WHO-AF-
RO regional documents and select national NTD programme master plans in Africa. We found that the 
policies and plans assume CDDs will implement NTD programmes, but there was little delineation of 
responsibilities or up-to-date practical guidance. This may signal an absence of explicit policy and pro-
gramme management, and this ambiguity probably impairs the effectiveness of these programmes.
Only three documents explicitly stated that CDDs will distribute drugs. Other tasks associated with drug 
distribution, such as health promotion, data collection and reporting, and clinical care, were also speci-
fied in few documents. These activities are fairly consistent with what was expected of CDDs under sin-
gle-disease control guidance from APOC [1]. Additional activities identified in the more recent policy 
documents included “MMDP delivery”, although what this constitutes was unclear. Some documents pro-
vided potential uses for CDDs, such as in delivery of bed nets and sensitisation for skin NTDs, and only 
one document from 2007 made a recommendation relating to CDDs [55]. Similarly, the role of CDDs in 
the national multi-year master plans was not explicit. For NTDs requiring drug distribution, the plans 
refer to community-based, use of CDTI/CDI structures, or MDA, with “volunteer training” listed as a re-
quirement alongside these strategies. Half of the country master plans also involve volunteers in either 
case management or transmission control, and most acknowledge CDDs participation in other tasks out-
side control of PC-NTDs.
Training and management for CDDs was one of the most frequently addressed topics, particularly in glob-
al policy. Across the documents there was more detail on supervisory and management tasks compared 
to training. The more comprehensive of the WHO documents were the three training courses/modules 
[33,52,53]. Between them, aspects of training, MDA commodities, examples of supervision tasks, forms 
and recommended management styles were presented, but there was little in the way of practical guid-
ance on how CDDs should conduct drug distribution and ancillary tasks (such as IEC) in integrated con-
trol programmes, let alone other service delivery. It is also not documented anywhere how many inter-
ventions CDDs can be responsible for. Training and supervision of CDDs was required by all the country 
master plans but reported variously. Training frequency ranged from annual in Nigeria and Cameroon 
to biannual in Ghana to quarterly in Liberia, and training was indicated for “integrated NTD activities” 
or “jointly for all the diseases” in some plans, and for specific functions such as “social mobilization” or 
“data collection reporting tools” in others. Details of CDD supervision and timing were less clearly for-
mulated across the master plans.
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Sustainability of community-based programmes relies on a committed, motivated and sufficiently incen-
tivised cadre of volunteers to deliver drug packages year after year and extend health interventions to 
communities underserved by current health systems. If the expectations are not clear, and if no one has 
responsibility to supervise them, then it is likely they will not be inspired to continue their voluntary work 
[63]. Incentives and CDD motivation were mentioned in some global and regional policy documents, and 
in all the country master plans; however, there was little consensus or solutions offered. For example, the 
governing body of APOC recommended developing a policy on incentives for volunteers at country lev-
els and urged governments to address the incentive issues [56,57]. This was reiterated in the lymphatic 
filariasis strategic plan, which stated: “…for volunteers… it will be necessary for health systems to create 
clear job descriptions, standardize incentives across programmes…”. However, other documents put the 
onus on the community to motivate volunteers [33]. The four country master plans all identified lack of 
motivation or high attrition of volunteers as threats or weaknesses to the NTD programme.
Poorly motivated volunteers and high attrition rates may be a consequence of the lack of clear guidance 
outlining the role of CDDs and how to train and supervise them, leading to uncertainty over responsi-
bilities and how to perform tasks. This is a common challenge identified across empirical literature that 
explores the experiences of CDDs and evaluates their engagement with programme implementation. Im-
proper training [64-66], insufficient supervision [67,68], confusion around responsibilities [69,70] and 
the limited amount of time allocated for workload [66,68,71] have all been reported in NTD programme 
literature. Recent studies and literature reviews have also highlighted that factors influencing CDD moti-
vation and performance include and extend beyond monetary and material incentives [72-74], although 
this is not unique to contemporary NTD volunteer schemes [75]. Intrinsic motivation, gender, cost to 
participate and health systems and community support were all identified as recurring themes in the 
literature [73]. Community support and the health system in particular were linked to motivation and 
performance, and in one study the CDDs who engaged friend groups with MDA were among the best 
performing CDDs [74]. Despite this evidence, and the possibly increased workload for CDDs through 
strategic scaling-up of national NTD programmes, most of the plans did not adequately address how vol-
unteers will be incentivised or motivated.
This lack of policy and planning frequently results in a lack of regulations or strict obligation to support 
CDD volunteerism, which may negatively impact their motivation and retention. To date, challenges to 
CDD performance based on health systems factors outlined above have been considered at the implemen-
tation level. However, this review highlights that there are also clear gaps in policy and implementation 
guidelines regarding the most effective ways to train, supervise and support CDDs to fulfil their role to 
the best of their ability. These gaps seem to have become greater overtime, indicating a reliance on pro-
gramme implementers to carry out business as usual in relation to the now historic CDTI strategy. CDDs 
are facing changing contexts, such as changes from rural distribution to growing urbanisation, fragile and 
conflict affected states, migration and nomadic communities, which also have CDDs. The role of CDDs has 
clearly evolved over the past two decades, but the changing nature of their role has not been reflected in 
policy and programme documentation. For example, a recent study of an integrated NTD programme in 
Uganda questioned some key assumptions of CDDs in community-based MDA, including the perceived 
altruism of volunteers (13.56% were considered as altruistic) and the need to select volunteers through 
community-wide meetings (selection method had no association with treatment rates) [74]. The study 
demonstrated that volunteer characteristics and involvement of their friend groups may be a better way 
to select and monitor CDD performance [74]. This would suggest that NTD programmes need to work 
within existing health system infrastructure to strengthen the level of support provided to this critical 
cadre, whilst also considering how to document their role and management requirements clearly within 
programme guidelines. Agreeing the role of this cadre at the national level, as well as the development of 
clear training, supervision and management tools, could be a critical first step toward improving CDD 
performance in many settings.
Whilst our review of policy has focused on the African situation for CDDs in NTD programmes, the find-
ings will likely apply to other global health programmes that rely on volunteers [76]. Given the diversity 
of health initiatives that rely on CHWs, who may also be unpaid volunteers not formally recognised by 
or integrated into health systems, and responsible for a myriad of tasks in the community, some ambi-
guity is to be expected. The recent publication of WHO guidelines on health policy and system support 
to optimise CHW programmes [77] is a step towards more formal recognition of their contributions in 
communities and the challenges faced by this cadre; however, our review has identified important issues 
in policy setting and programme planning that are probably reflected in other volunteer schemes oper-
ating worldwide.
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For this review, we attempted to identify WHO policies and plans that include CDDs as they are known 
by NTD programmes, which also involved searching broader CHW documents. Therefore, a key strength 
of this review is that it brings together all the CDD policy documents produced over the last ten years 
and indicates a key documentation gap, which is important in progressing NTD programmes. A poten-
tial weakness may lie in not reviewing national programme standard operating procedures (SOPs) and 
other policies that may impact on the CDDs role or management. For example, Nigeria’s Federal Ministry 
of Health has produced documents such as the “training guide for trainers of community implementers 
(CIs) on NTD control and elimination”, while in Liberia the role of CHWs and CDDs has become more 
formalised, where the programme is now encouraged not to use CDDs but to implement through the new 
CHW policy [78]. Our review has also given less attention to the role of CDDs within other NTD service 
delivery, such as integrated case management, as we did not find explicit evidence of their responsibilities 
in this beyond that which is documented in the national master plans. However, as global and regional 
policy and national master plans form the basis for NTD policy setting and programme implementation 
guidance, we feel this review highlights critical areas that need to be addressed.
CONCLUSIONS
Global and African WHO policy documents assume the implementation of CDDs but provide little guidance 
for their roles and how to prepare and utilise them within integrated programmes and changing contexts.
Given the changes in diseases covered, and adding of tasks such as morbidity control, case management, 
and distribution of other commodities, it seems likely the ambiguity and growth of tasks will, in the ab-
sence of clear guidance, regular training and active management at both national and local level, contrib-
ute to these programmes failing to assure equitable drug delivery to people.
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